menu
    • menu
    [{"orgOrder":0,"company":"Epion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Epion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Epion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Epion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Epion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Price Vision Group","sponsor":"Cornea Research Foundation of America","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Price Vision Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Price Vision Group \/ Cornea Research Foundation of America","highestDevelopmentStatusID":"9","companyTruncated":"Price Vision Group \/ Cornea Research Foundation of America"},{"orgOrder":0,"company":"Peschke","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peschke","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Peschke \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Peschke \/ Inapplicable"},{"orgOrder":0,"company":"Colorado Eye Consultants","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Colorado Eye Consultants","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Colorado Eye Consultants \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Colorado Eye Consultants \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"University of Ulster","sponsor":"DSM Ltd | Public Health Agency (Northern Ireland)","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"University of Ulster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulster \/ DSM Ltd | Public Health Agency (Northern Ireland)","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulster \/ DSM Ltd | Public Health Agency (Northern Ireland)"},{"orgOrder":0,"company":"University of Ulster","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Ulster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulster \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulster \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Clinical Research Consultants, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Clinical Research Consultants, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Clinical Research Consultants, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clinical Research Consultants, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Analyze & Realize"},{"orgOrder":0,"company":"Clinical Research Consultants, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Clinical Research Consultants, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Clinical Research Consultants, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clinical Research Consultants, Inc. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000634

    Menu

    Prestwick3_000634

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Clinical Research Consultants, Inc.

                            Country arrow
                            ESCRS
                            Not Confirmed

                            Clinical Research Consultants, Inc.

                            Country arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epi-ON Corneal Crosslinking UVA Safety In Down Syndrome with Ectatic Corneal Diseases

                            Details : Vitamin B2 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Down Syndrome.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            August 21, 2025

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Clinical Research Consultants, Inc.

                            Country arrow
                            ESCRS
                            Not Confirmed

                            Clinical Research Consultants, Inc.

                            Country arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epi-ON Corneal Crosslinking 18-Min Vs 24-Min UVA Exposure Safety and Efficacy

                            Details : Riboflavin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Keratoconus.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            August 15, 2025

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Royal DSM

                            Netherlands arrow
                            ESCRS
                            Not Confirmed

                            Royal DSM

                            Netherlands arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Analyze & Realize

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Colon-delivered Riboflavin and Gut Microbiota Composition

                            Details : Riboflavin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Dysbiosis.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            July 30, 2025

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Analyze & Realize

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Glaukos

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

                            Details : Epioxa (riboflavin) is a small molecule drug candidate, which is being evaluated for the treatment of patients with progressive keratoconus.

                            Product Name : Epioxa

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            February 24, 2025

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Glaukos

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

                            Details : Epioxa (riboflavin) is a small molecule drug candidate, which is being evaluated for the treatment of patients with progressive keratoconus.

                            Product Name : Epioxa

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            December 23, 2024

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Glaukos

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glaukos Achieves Primary Endpoint in Phase 3 Epioxa™ Trial for Tolerability

                            Details : Epioxa (riboflavin) is a small molecule drug candidate, which is being evaluated for the treatment of patients with progressive keratoconus.

                            Product Name : Epioxa

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 16, 2024

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Epion Therapeutics

                            Country arrow
                            ESCRS
                            Not Confirmed

                            Epion Therapeutics

                            Country arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 25, 2023

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Epion Therapeutics

                            Country arrow
                            ESCRS
                            Not Confirmed

                            Epion Therapeutics

                            Country arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 25, 2023

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Royal DSM

                            Netherlands arrow
                            ESCRS
                            Not Confirmed

                            Royal DSM

                            Netherlands arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Atlantia Food Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Colon Delivered Vitamin B2 on Gut Microbiota and Related Health Biomarkers in Healthy Older Adults

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            April 07, 2023

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Atlantia Food Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            University of Ulster

                            Country arrow
                            ESCRS
                            Not Confirmed

                            University of Ulster

                            Country arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intervention With Riboflavin to Improve Vascular Health and ENdothelial Functioning in Genetically at- Risk Ad...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth